Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1819 in Moderate to Severe Atopic Dermatitis
NCT06468956Phase 3Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Jun 2024
- Primary completion
- Aug 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of SHR-1819 in atopic dermatitis (AD), sponsored by Hengrui Therapeutics. Started Jun 2024; status: completed.
02
Drugs
SHR-1819
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06468956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06468956.